9-in-1 cervical cancer vaccine
Human papillomavirus (HPV) is an important cause of cervical cancer. 99.7% of cervical cancer is caused by HPV infection. Among them, 16, 18, 31, 33, 45, 52 and 58 types can lead to up to 90% cervical cancer, 90-95% anal cancer, 90% vulvar cancer, 85% vaginal cancer and related precancerous lesions.
The current 9-in-1 cervical cancer vaccine is a preventive vaccine, which can effectively prevent nine types of HPV, including two low-risk types 6, 11 and seven high-risk types 16, 18, 31, 33, 45, 52, 58. Ninety percent reduce the risk of genital warts, commonly known as “broccoli”. For men, it can reduce the risk of anal cancer, genital warts (commonly known as “broccoli”) and transmission of HPV virus.
Who is suitable for HPV cervical cancer vaccination?
Both boys and girls aged 9 or above are suitable for HPV vaccination. It is generally recommended that they be vaccinated before they have sexual experience, which can maximize their effectiveness and reduce the chances of developing cervical cancer and other cancers more effectively. Vaccines do not affect development and menstruation.
Women infected with HPV had two high stages, 26 to 30 and 46 to 55 years old, respectively. The high stages of HPV development into cervical cancer were 41 to 45 and 66 to 70 years old. Vaccination for sexually experienced women is still very effective in preventing certain types of HPV that have not been infected. Among women aged 14-59, only 0.1% were infected with HPV 16 and 18 at high risk, so vaccination was effective against the risk of infection in the future.
Does HPV cervical cancer vaccine have side effects?
The vaccine has undergone clinical studies for women worldwide and has been approved by the FDA of the Food and Drug Administration of the United States. It has been registered in more than 120 countries and regions worldwide, and has injected more than 300 million doses.
Side effects are similar to those of other vaccines and no serious cases have been found so far. It is only common that there may be redness and pain in the vaccinated area; fever, nausea, dizziness or headache may occur in a small number of people.
Pregnant women or patients with poor immunity are advised to consult a doctor before vaccination.
Suggested time for vaccination (three doses in total)?
First dose: start at any time
Second dose: 2 months after the first dose
Third dose: 6 months after the first dose
* Three doses of vaccination must be completed within one year